As the UK transforms its ecosystem for clinical trials, the regulatory landscape is undergoing its biggest change in 20 years. In this third episode of this free New Scientist podcast, we meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program.More from this series:In Episode 1 we meet the chair of the UK review into commercial clinical trials, James O'ShaughnessyIn Episode 2 we hear from Professor Andrea Manfrin whose team is responsible for driving this change at the Medicines and Healthcare products Regulatory AgencyRead more here and watch a video summarising the series.Sponsored by the UK Department for Business and Trade and the Medicines and Healthcare products Regulatory Agency